- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01824264
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
April 2, 2014 updated by: Novartis Pharmaceuticals
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Evaluate Change in HbA1c After 12 Weeks Monotherapy With 7 Doses of LIK066 Compared With Placebo or Sitagliptin in Patients With Type 2 Diabetes
The purpose of the study is to evaluate the efficacy, tolerability and short-term safety of LIK066 to support dose selection for phase 3.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed diagnosis of T2DM by standard criteria
- Drug-naïve patients, defined as patients not having received any anti-diabetic medication previously,
- Currently untreated patients , who, after the diagnosis of T2DM, have received anti-diabetic medication for not more than 12 consecutive weeks, and have not received any anti-diabetic treatment within 12 weeks prior to Visit 1
- Patients being treated with mono-therapy for at least 8 consecutive weeks prior to Visit 1 with the following OADs: metformin, dipeptidyl peptidase-4 inhibitors (DPP-4i), SU, glinide, alpha-glucosidase inhibitor (AGI)
- HbA1c ≥ 7 to ≤ 10.5% at Visit 1 for drug-naïve/currently untreated patients
- HbA1c ≥ 7 to ≤ 9.5% at Visit 1 for patients treated with OAD monotherapy
- HbA1c ≥ 7 to ≤ 10.5% at Visit 199 for ALL patients
- Age: ≥18 and ≤ 75 years old at Visit 1
- BMI ≥22 to ≤45 kg/m2 at Visit 1
Exclusion Criteria:
- FPG ≥270 mg/dl (15 mmol/L) for drug-naïve/currently untreated patients or ≥240 mg/dl (13.3 mmol/L) for patients on OAD monotherapy at Visit 1
- Insulin treatment >4 consecutive weeks in the last 6 months, corticosteroid use >7 days in the last 8 weeks, use of growth hormones in the last 6 months, or use of weight control products > 4 weeks in the last 6 months
- History of acute metabolic complications, CV disease, type 1 diabetes mellitus, hepatic disorders, pancreatitis, chronic diarrhea
- Significant lab abnormalities such as TSH outside of normal range, UACR>300 mg/g creatinine, eGFR <60 ml/min/1.73m2, hemoglobin <12 g/L in men and <11 g/L in women, hematuria
- ECG abnormalities including AV block, long QT syndrome or QTc>450 msec for men and >470 msec for women
- History of malignancy
- Women of child-bearing potential not using effective methods of contraception Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LIK066 2.5 mg
Patients receive 2.5 mg of LIK066 once daily for 12 weeks
|
Experimental treatment doses
|
Experimental: LIK066 5 mg
Patients receive 5 mg of LIK066 once daily for 12 weeks
|
Experimental treatment doses
|
Experimental: LIK066 10 mg
Patients receive 10 mg of LIK066 once daily for 12 weeks
|
Experimental treatment doses
|
Experimental: LIK066 25 mg
Patients receive 25 mg of LIK066 once daily for 12 weeks
|
Experimental treatment doses
|
Experimental: LIK066 50 mg
Patients receive 50 mg of LIK066 once daily for 12 weeks
|
Experimental treatment doses
|
Experimental: LIK066 100 mg
Patients receive 100 mg of LIK066 once daily for 12 weeks
|
Experimental treatment doses
|
Experimental: LIK066 150 mg
Patients receive 150 mg of LIK066 once daily for 12 weeks
|
Experimental treatment doses
|
Active Comparator: Sitagliptin 100 mg
Patients receive 100 mg sitagliptin once daily for 12 weeks
|
Active comparator treatment dose
|
Placebo Comparator: Placebo
Patients receive placebo for 12 weeks
|
Placebo comparator dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks
Time Frame: baseline, 12 weeks
|
Change from baseline in HbA1c after 12 weeks of treatment in each of the LIK066 doses and placebo
|
baseline, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Fasting Plasma Glucose
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on fasting plasma glucose after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in urinary glucose to creatinine ratio
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on urinary glucose to creatinine ratio after 12 weeks of treatment will be evaluated
|
baseline, 12 weeks
|
Change from baseline in Body weight
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on change in body weight after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in Blood pressure
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on change in systolic and diastolic blood pressure after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in postprandial glucose during a meal test
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on change in postprandial glucose during a meal test after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in beta cell function during a meal test
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on change in beta cell function during a meal test after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in insulin secretion relative to glucose during a meal test
Time Frame: baseline, 12 weeks
|
The effect of LIK066on change in insulin secretion relative to glucose during a meal test after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in oral glucose insulin sensitivity during a meal test
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on change in oral glucose insulin sensitivity during a meal test after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in glucagon-like peptide response during a meal test
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on change in glucagon-like peptide during a meal test after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Change from baseline in Peptide YY response during a meal test
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on change in peptide YY response during a meal test after 12 weeks of treatment will be evaluated.
|
baseline, 12 weeks
|
Number of patients with adverse events to assess safety and tolerability of LIK066
Time Frame: 12 weeks
|
The safety and tolerability of 7 doses of LIK066 after 12 weeks of treatment will be evaluated with number of patients reported for total adverse events, serious adverse events and death.
|
12 weeks
|
Change from baseline in renal threshold for glucose excretion
Time Frame: baseline, 12 weeks
|
The effect of LIK066 on renal threshold for glucose excretion will be calculated from glucose values in an overnight urine collection
|
baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Anticipated)
November 1, 2016
Study Completion (Anticipated)
November 1, 2016
Study Registration Dates
First Submitted
April 1, 2013
First Submitted That Met QC Criteria
April 1, 2013
First Posted (Estimate)
April 4, 2013
Study Record Updates
Last Update Posted (Estimate)
April 3, 2014
Last Update Submitted That Met QC Criteria
April 2, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Sodium-Glucose Transporter 2 Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Sitagliptin Phosphate
- Licogliflozin
Other Study ID Numbers
- CLIK066A2202
- 2012-005793-63 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States